Become A Featured Company

Lexaria Approaches Tipping Point with New Products & Financing

Ryan Allway

April 5th, 2017

News, Top News

The market for cannabidiol (“CBD”) is expected to grow to a $2.1 billion market in consumer sales by 2020, according to the Hemp Business Journal, with about $450 million of those sales coming from hemp-based sources. While there are plenty of companies involved in selling hemp-based CBD products, there are few options for solving the problems associated with the bioavailability of CBDs, which tends to be lacking in many products.

In this article, we will take a closer look at Lexaria Corp.’s (OTCQB: LXRP) recent capital raise and launch of new products into the market.

Innovative New Products

Lexaria recently announced the launch of its TurboCBD™ brand of enhanced, high-absorption, full-spectrum hemp oil capsules. The capsules incorporate the company’s patented absorption technology – proven to increase CBD absorption by five to ten times compared to conventional preparations – along with the finest American Ginseng and Ginkgo Biloba to support enhanced focus and memory as well as reduced stress and fatigue.

The company plans to showcase the TurboCBD™ capsules at the upcoming 2017 World Medical Marijuana Business Conference & Expo in Pittsburgh, PA on April 21 and 22, which is expected to attract over 8,000 cannabis professionals, including 1,200 physicians interested in the sector. The company also plans to distribute the new product through California medical cannabis dispensaries and select locations as the perfect complement to cannabis.

In addition to TurboCBD™, the company plans to launch other capsule formulations utilizing its patented absorption technology to address specific market demands. Management is also developing and seeking opportunities to leverage its technology for tetrahydrocannabinol (“THC”) product applications through licensees in the United States, Canada, and other countries around the world – potentially opening the door to new markets.

Growth Capital in Place

Lexaria has leveraged a combination of public and private capital to support the development of its innovative portfolio of products. With this combination, the company is able to offset some of its research and development expenses to bring products to market more quickly and effectively than ever possible.

On April 3, the company announced the completion of a brokered private placement of 4,104,280 units at a price of US$0.42 each for total gross proceeds of US$1,723,798. The units of the offering consist of one common share and one-half share purchase warrant at a price of US$0.60 per share for a 24-month period. The proceeds of the offering will be used to advance the research and development of its patented delivery technology.

In addition the company raised in excess of US$1 million in recent months from existing shareholders who have exercised existing warrants and stock options.

The most recent capital raise also marks the first time ever that the company has a runway of greater than one year, which will help limit future dilution. In fact, Lexaria is better capitalized today than at any point in its history, giving the company its best-ever opportunity to leverage its technology to the benefit of its B2B partners.

The equity financing announcement comes shortly after the company announced that it was formalizing studies in concert with the National Research Council of Canada (“NRC”). These studies will be specifically designed to evaluate and determine the best methods for introducing heat, optimal temperatures attained, duration of heat and air exposure, and other criteria for processing lipophilic active agents within foods and other substances like cannabinoids. The NRC is owned by the Federal Government of Canada and is one of the most highly regarded scientific research agencies in the world.

Looking Ahead

Lexaria Corp. (OTCQB: LXRP) is uniquely positioned to capture market share within the $2.1 billion CBD industry. With its innovative delivery system, the company’s products offer significantly enhanced bioavailability compared to competing products. The recent launch of new products and secured financing opens the door to significant revenue growth ahead and investors may want to keep a close eye on the stock.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading